How did average weight loss go from 8 to 28.7 percent?
GLP-3 acts on three signalling pathways:
GLP-1, GIP and glucagon.
Four compounds. One decade.
Each generation targets more of the body’s metabolic pathways.

Signal 1
GLP-1 receptorGLP-1
Carries the satiety signal from gut to brain
Signal 2
GIP receptorGIP
Acts on glucose handling and on fat tissue
Signal 3
Glucagon receptorGlucagon
Tells the liver to release stored energy
2025
Retatrutide
28.7%Average weight loss in trials
2022
Tirzepatide
22.5%Average weight loss in trials
2021
Semaglutide
15%Average weight loss in trials
2015
Liraglutide
8%Average weight loss in trials
What the Phase 3 trials measured
About GLP-3
Body Composition
28.7% Average weight loss in trials
76% Improvement in joint pain
1 in 8 Reported complete pain relief
Cardiovascular
14-pt Drop in blood pressure
27% Drop in non-HDL cholesterol (Harmful type)
41% Reduction in triglycerides (Blood fats)
Metabolic
86% Average liver fat reduction
93% Saw liver fat return to normal
71% Drop in fasting insulin
GLP-3 RT
Three targets. One peptide
- GLP-1 carries the satiety signal from gut to brain
- GIP acts on glucose handling and on fat tissue
- Glucagon tells the liver to release stored energy
Research use onlyGet Catalyst →
For educational purposes only. Not medical advice. Consult a healthcare professional.